Emerging role of METTL3 in inflammatory diseases: mechanisms and therapeutic applications

Frontiers in Immunology

Immunology

Jiamin Zhang¹  Xida Zhao¹  Yaping Pan¹  Jingbo Liu¹  Bimei Song¹  Yue Zeng¹  Yanqing Cao¹  Chao Xu¹ 

[1] Department of Periodontics, School of Stomatology, China Medical University, Shenyang, China;

关键词: m6A modification;    METTL3;    inflammation;    inflammatory diseases;    immune cell;    therapy;   

DOI  :  10.3389/fimmu.2023.1221609

 received in 2023-05-12, accepted in 2023-07-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

Despite improvements in modern medical therapies, inflammatory diseases, such as atherosclerosis, diabetes, non-alcoholic fatty liver, chronic kidney diseases, and autoimmune diseases have high incidence rates, still threaten human health, and represent a huge financial burden. N6-methyladenosine (m6A) modification of RNA contributes to the pathogenesis of various diseases. As the most widely discussed m6A methyltransferase, the pathogenic role of METTL3 in inflammatory diseases has become a research hotspot, but there has been no comprehensive review of the topic. Here, we summarize the expression changes, modified target genes, and pathogenesis related to METTL3 in cardiovascular, metabolic, degenerative, immune, and infectious diseases, as well as tumors. In addition to epithelial cells, endothelial cells, and fibroblasts, METTL3 also regulates the function of inflammation-related immune cells, including macrophages, neutrophils, dendritic cells, Th17 cells, and NK cells. Regarding therapeutic applications, METTL3 serves as a target for the treatment of inflammatory diseases with natural plant drug components, such as emodin, cinnamaldehyde, total flavonoids of Abelmoschus manihot, and resveratrol. This review focuses on recent advances in the initiation, development, and therapeutic application of METTL3 in inflammatory diseases. Knowledge of the specific regulatory mechanisms involving METTL3 can help to deepen understanding of inflammatory diseases and lay the foundation for the development of precisely targeted drugs to address inflammatory processes.

【 授权许可】

Unknown   
Copyright © 2023 Song, Zeng, Cao, Zhang, Xu, Pan, Zhao and Liu